KH
Kamlesh Himatlal Dattani
About Kamlesh Himatlal Dattani
Data last updated:
Kamlesh Himatlal Dattani has 2 years in corporate governance. Holds Director role. Currently with 1 company, including Prince Supplico Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Prince Supplico Pharma Private Limited at ₹9.97 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Prince Supplico Pharma Private Limited U46497GJ2024PTC153116 | Director | 02 Jul 2024 | 2024 | ₹9.97 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kamlesh Himatlal Dattani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kamlesh Himatlal Dattani
Kamlesh Himatlal Dattani has 2 years in corporate governance. Holds Director role. Currently with 1 company, including Prince Supplico Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Prince Supplico Pharma Private Limited at ₹9.97 Cr (FY 2025).
Kamlesh Himatlal Dattani is associated with 1 company as Director, including Prince Supplico Pharma Private Limited (₹9.97 Cr).
Kamlesh Himatlal Dattani has expertise in General Business.
Kamlesh Himatlal Dattani has 2 years in corporate governance.
By reported revenue, the largest current company of Kamlesh Himatlal Dattani is Prince Supplico Pharma Private Limited, with revenue of ₹9.97 Cr (FY 2025).
Kamlesh Himatlal Dattani currently holds positions at 1 company: Prince Supplico Pharma Private Limited (₹9.97 Cr).